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Recessive Mutations in the Putative Calcium-Activated
Chloride Channel Anoctamin 5 Cause Proximal LGMD2L
and Distal MMD3 Muscular Dystrophies
Ve´ronique Bolduc,1,13 Gareth Marlow,2,13 Kym M. Boycott,3 Khalil Saleki,2 Hiroshi Inoue,4
Johan Kroon,2 Mitsuo Itakura,4 Yves Robitaille,5 Lucie Parent,6 Frank Baas,7 Kuniko Mizuta,9
Nobuyuki Kamata,9 Isabelle Richard,10 Wim H.J.P. Linssen,11 Ibrahim Mahjneh,12
Marianne de Visser,8 Rumaisa Bashir,2 and Bernard Brais1,*
The recently described human anion channel Anoctamin (ANO) protein family comprises at least ten members, many of which have
been shown to correspond to calcium-activated chloride channels. To date, the only reported human mutations in this family of genes
are dominant mutations in ANO5 (TMEM16E, GDD1) in the rare skeletal disorder gnathodiaphyseal dysplasia. We have identiﬁed reces-
sive mutations in ANO5 that result in a proximal limb-girdle muscular dystrophy (LGMD2L) in three French Canadian families and in
a distal non-dysferlin Miyoshi myopathy (MMD3) in Dutch and Finnish families. These mutations consist of a splice site, one base pair
duplication shared by French Canadian and Dutch cases, and two missense mutations. The splice site and the duplication mutations
introduce premature-termination codons and consequently trigger nonsense-mediated mRNA decay, suggesting an underlining loss-
of-functionmechanism. The LGMD2L phenotype is characterized by proximal weakness, with prominent asymmetrical quadriceps fem-
oris and biceps brachii atrophy. The MMD3 phenotype is associated with distal weakness, of calf muscles in particular. With the use of
electron microscopy, multifocal sarcolemmal lesions were observed in both phenotypes. The phenotypic heterogeneity associated with
ANO5mutations is reminiscent of that observed with Dysferlin (DYSF) mutations that can cause both LGMD2B and Miyoshi myopathy
(MMD1). In one MMD3-affected individual, defective membrane repair was documented on ﬁbroblasts by membrane-resealing ability
assays, as observed in dysferlinopathies. Though the function of the ANO5 protein is still unknown, its putative calcium-activated chlo-
ride channel functionmay lead to important insights into the role of deﬁcient skeletal musclemembrane repair inmuscular dystrophies.Muscular dystrophies encompass a large and diverse group
of inherited diseases deﬁned by skeletal muscle weakness
and atrophy. Among these, the limb-girdle muscular
dystrophies (LGMD) represent a group of both dominant
and recessive disorders, characterized by predominant
proximal limb muscle weakness, with 18 known causal
genes.1,2 The majority of the proteins involved in LGMD
are important for maintaining the integrity of the sarco-
lemmal membrane, which is susceptible to injury because
of the high mechanical stress imposed on muscle ﬁbers
during muscle contraction.1,3 Some of the implicated
proteins, such as the Sarcoglycans (LGMD2C-2F [MIM
253700, 608099, 604286, 601287]), when mutated disrupt
the normal structure and hence the stability of the
membrane.4 Another group of mutated proteins, such as
Dysferlin (MIM 603009) (LGMD2B [MIM 253601]) and
Caveolin-3 [MIM 601253] (LGMD1C [MIM 607801]),
play a role in the repair of damaged muscle membrane
through a process that requires the recruitment of cyto-
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The Americafusion by exocytosis to form a patch membrane.5–8 The
distal myopathies are also a large group of muscular dystro-
phies with more than ten genes identiﬁed to date charac-
terized by initial distal limb weakness.9 In the cases of dys-
ferlinopathies, both a proximal LGMD2B phenotype and a
distal Miyoshi myopathy phenotype (MM [MIM 254130])
are caused by mutations in the Dysferlin (DYSF) gene.10–12
The human Anoctamins (ANO) compose a family of at
least ten proteins all exhibiting eight transmembrane
domains and a DUF590 domain of unknown function.13,14
Recently, ANO1 (MIM 610108), ANO2 (MIM 610109),
ANO6 (MIM 608663), ANO8 (MIM 610216), and ANO9
have been recognized to code for the elusive calcium-
activated chloride channels (CaCC);15–20 however, the
function of ANO5 (MIM 608662) is unknown. In this study
we report that recessive mutations in Anoctamin 5 (ANO5)
cause both a proximalmuscular dystrophy, LGMD2L (MIM
611307), and the distal Miyoshi myopathy MMD3.
A previous study mapped LGMD2L, a novel recessive
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Figure 1. Identification of ANO5 Mutations in French Canadian LGMD2L Families
(A) Pedigrees of LGMD2L families IX and XXXI. Parents of the two families are ﬁrst-degree cousins. Genotypes for the c.1295C>G
variant are indicated below the individuals for whom DNA was available. Family IX has been described earlier.21
(B) Genomic sequence chromatogram of exon 13 in patient IX-II-9 reveal an exonic substitution (c.1295C>G). Sequencing of ANO5 in
the two families in (A) conﬁrmed that affected individuals IX-II-3, IX-II-4, IX-II-5, XXXI-II-3, and XXXI-II-11 were also homozygous for
the mutation.
(C) cDNA amplicons of ANO5 exons 10 to 15 from muscle RNA samples for patient IX-II-9 and a control individual.
(D) Sequence chromatograms of the cDNA amplicons in (C) in the region of the nucleotide c.1295.
(E) Pedigree of LGMD2L family XXIX. Genomic sequence chromatograms show that patient XXIX-II-1 is compound heterozygote for
two exonic variants: a 1 bp duplication in exon 5 (c.191 dupA) and a missense mutation in exon 8 (c.692G>T/G231V). Her unaffected
brother is a carrier for the c.191 dupA.
(F) Protein alignment of the G231 residue in ANO5 via Multiz.quadriceps femoris and biceps brachii atrophy, to chromo-
some 11p12-p13 in a cohort of French Canadian (FC) fami-
lies.21 SNP genotyping via the Illumina HumanHap300
beadchip (317 503 SNPs; Illumina, San Diego, CA) was
performed on the previously reported single large consan-
guineous FC Family IX21 (Figure 1A) at the McGill Univer-
sity and Genome Que´bec Innovation Centre genotyping
platform. Homozygosity analysis via AutoSNPa22 identi-
ﬁed a 4.7 Mb region of homozygosity on chromosome
11p14.3-p15 (616 consecutive SNPs delimited by
rs4073508 and rs10834273). This new region shifted telo-
merically by 11.9 Mb the previous published candidate
interval (11p12-p13).21 This region contained 11 anno-214 The American Journal of Human Genetics 86, 213–221, Februarytated genes: NAV2 (MIM 607026), DBX1, HTATIP2 (MIM
605628), PRMT3 (MIM 603190), SLC6A5 (MIM 604159),
NELL1 (MIM 602319), ANO5/TMEM16E, FANCF (MIM
603467), GAS2 (MIM 602835), SLC17A6 (MIM 607563),
and SVIP. The exons and intron-exon junctions were
sequenced for ﬁve of these genes: ANO5/TMEM16E,
FANCF, GAS2, SLC17A6, and SVIP. Mutations were identi-
ﬁed in ANO5/TMEM16E in family IX. Though the
sequencing of ANO5 exons and intron-exon borders in
the seven remaining families of the original cohort21 did
not identify mutations, the screening of two new FC
LGMD2L families identiﬁed other mutations in ANO5.
Informed consent approved by the Centre Hospitalier de12, 2010
l’Universite´ de Montre´al ethics committee was obtained
for all participants. In Family IX we identiﬁed a homozy-
gous nucleotide substitution (c.1295C>G) in genomic
DNA, which creates a putative splice donor site within
exon 13 as calculated by NetGene2 and Human Splicing
Finder v2.4 (Figures 1A and 1B). Ampliﬁcation and
sequencing of patient muscle cDNA conﬁrmed the aber-
rant splicing of exon 13 that results in the deletion of
the last 38 nucleotides of this exon (Figures 1C and 1D),
leading to a frameshift and a predicted premature trunca-
tion (p.Ala432GlyfsX49). Segregation of this variant in
Family IX was conﬁrmed by sequencing the genomic
DNA of exon 13 in all siblings (Figure 1A). The same muta-
tion was identiﬁed in homozygote state in the two cases
belonging to the FC Family XXXI (Figure 1A). The two
families are not known to be related and come from
different regions, but share a six STR markers haplotype
(covering 3.6 Mb), suggesting that it is the same historical
mutation that segregates in these families (data not
shown). The third LGMD2L FC Family XXIX was heterozy-
gous for two other variants: c.191 dupA in exon 5
(p.Asn64LysfsX15) and c.692G>T in exon 8 (p.G231V)
(Figure 1E). The G231 residue is evolutionary conserved
(Figure 1F) and is predicted to be located in the putative
intracellular N-terminal tail (Figure 2D). Sequencing of
the entire 87 kb genomic region of ANO5 is underway to
identify mutations in other FC LGMD families.
Further evidence that ANO5 mutations cause muscular
dystrophy came from an independent study of families
presenting with a distal non-dysferlin Miyoshi myopathy.
Informed consents approved by the Kainuu Central
Hospital (Finland), the Academic Medical Centre (The
Netherlands), and the University of Durham (United
Kingdom) ethical committees were obtained for these
families. Two Miyoshi myopathy families, in which muta-
tions in DYSF and linkage to the 10p MMD2 locus had
been excluded,23 were genotyped via the Affymetrix Gen-
eChip Human Mapping 50k (performed by AROS Applied
Biotechnology, Aarhus Nord, Denmark). They were linked
to a Miyoshi myopathy (MMD3) locus on chromosome
11p14.3-cen (rs722490 to rs509244, cumulative LOD score
of>2.5) overlapping with the LGMD2L candidate region21
(data not shown). Sequencing of the ANO5 gene identiﬁed
mutations in both families. In the Finnish Family H,24
a homozygous nucleotide substitution (c.2272C>T) was
identiﬁed in exon 20 that leads to the substitution of
a conserved arginine to a cysteine residue (R758C; Fig-
ure 2A). The same heterozygote exon 5 mutation (c.191
dupA) observed in the FC Family XXIX (Figure 1E) was
found in a homozygous state in the Dutch Family IV23 (Fig-
ure 2B). Both variants were shown to segregate with the
disease in the two families. None of the mutations have
been reported as variants in the following databases: the
National Center for Biotechnology Information (NCBI)
database of genetic variation (dbSNP build 130), the
Human Genome Diversity Project in collaboration with
the Centre d’E´tude du Polymorphisme Humain (HGDP-The AmericaCEPH), and the International HapMap Project (Merged
phases 1, 2, & 3). Considering that the ﬁve ANO5 families
have diverse origins (three FC, one Dutch, and one
Finnish), we tested their carrier frequencies in these three
populations, as well as in panels of United Kingdom (UK)
Caucasian controls (from the Health Protection Agency
of United Kingdom) and CEPH controls. The c.1295C>G
variant was absent in 210 FC and 162 CEPH control chro-
mosomes, and the c.692G>T (G231V) variant was absent
in 210 FC control chromosomes. The c.2272C>T
(R758C) variant was not detected in 100 UK, nor in 208
FC, control chromosomes, but was detected in one out of
368 Finnish control chromosomes, indicating that this
variant is present in the Finnish population at low
frequency. The c.191 dupA mutation was absent in 210
FC and in 152 CEPH control chromosomes, but was iden-
tiﬁed in 1 out of 100 UK and in 2 out of 210 Dutch control
chromosomes. The observed absence or very low popula-
tion frequencies of the ANO5 mutations strongly support
our conclusion that these cause LGMD2L and MMD3.
ANO5 is predicted to produce several alternatively
spliced isoforms, with the major isoform in muscle retain-
ing all 22 exons.25 Based on the predicted full coding
sequence (NCBI reference sequence NM_213599.2), it is
expected that the mutations c.1295C>G (LGMD2L) and
c.191 dupA (LGMD2L and MMD3) lead to a frameshift
and premature truncation (p.Ala432GlyfsX49 and
p.Asn64LysfsX15, respectively; Figure 2D). As is often the
case with mRNAs containing premature termination
codons, a translation-coupled nonsense-mediated RNA
decay (NMD) mechanism may lead to their more rapid
degradation.26 To test whether transcripts carrying the
mutations c.1295C>G and c.191 dupA are subject to
NMD, lymphoblastoid cell lines isolated from EBV-trans-
formed lymphocytes were grown in IMDM medium (Invi-
trogen, Carlsbad, CA) supplemented with 10% Fetal
Bovine serum (Invitrogen) and incubated for 9 hr with
0.1% DMSO (vehicle) or 100 mg/mL of cycloheximide
(Sigma, St. Louis, MO), a translation inhibitor. Quantita-
tive RT-PCR were performed in triplicate on extracted
RNA, and expression of ANO5 was normalized to a set of
three control genes (GAPDH [MIM 138400], PUM1 [MIM
607204], and RPL13A) via QBase, a modiﬁed DDCt
method,27 at the Ge´nome Que´bec and Universite´ de Sher-
brooke RNomics Centre. All controls and cases demon-
strated an increase in the relative ANO5 expression as a
consequence of cycloheximide treatment (Figure 3A);
however, the differential ANO5 expression between cyclo-
heximide-treated and untreated cells was signiﬁcantly
greater in patients homozygous for c.1295C>G (n ¼ 2)
versus controls (n ¼ 3, p < 0.001, Student’s t test;
Figure 3B), suggesting that the mutated transcripts were
protected from NMD when translation was inhibited.
The approximate 5-fold increase observed for case XXIX-
II-1 (Figure 3A), as compared to the 8- and 9-fold increases
observed for the two c.1295C>G aberrant splicing
mutation homozygote cases, is in agreement with hern Journal of Human Genetics 86, 213–221, February 12, 2010 215
Figure 2. Identification of ANO5 Mutations in Non-Dysferlin Miyoshi Myopathy Families
(A) Genomic sequence chromatograms of exon 20 of ANO5 show that in the non-dysferlin MM Finnish family H that is linked with
defective membrane repair,24 there is a homozygous nucleotide substitution that would result in an amino acid substitution
(c.2272C>T/R758C).
(B) In the MMD3 Dutch family IV, the mutation identiﬁed is c.191 dupA in exon 5 inherited as homozygous. The same mutation is
present as heterozygous in the LGMD2L Family XXIX.
(C) EM micrograph of patient II-6 muscle from Family H highlights multifocal loss of sarcolemmal membrane. Magniﬁcation 35000.
Scale bar represents 5 mm.
(D) Predicted structure of human ANO5 and the relative position of the GDD1, LGMD2L, and MMD3 mutations. ANO5 is predicted to
contain eight transmembrane (TM) domains with both the N-terminal and the C-terminal regions located intracellularly. The DUF590
domain contains at last three TM domains (TM6-8). The MMD3 R758C mutation that is associated with defective membrane repair is
located extracellularly as are the two GDD mutations. The LGMD2L mutations and one MMD3 mutation are located to intracellular
regions.
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Figure 3. Analysis of ANO5 Expression
after Cycloheximide Treatment in
Patients Carrying Mutations Producing
Premature Terminations
(A) ANO5 relative expression in lympho-
blastoid cell lines treated with 100 mg/ml
of the translation inhibitor cycloheximide
for 9 hr as compared to cells treated with
vehicle (0.1% DMSO). A greater increase
was observed for all three patients (9-, 8-,
and 5.5-fold) compared to controls
(2-fold). Data represent means5 standard
errors of the experimental triplicates.
Patients IX-II-9 and XXXI-II-11 are homo-
zygous for c.1295C>G, causing an aber-
rant splicing in exon 13, a frameshift,
and a premature termination codon. Patient XXIX-II-1 is heterozygote for c.191 dupA, causing a frameshift and a premature stop codon,
and for c.692G>T, predicted to result in a missense.
(B) The differential expression represents the ANO5 expression ratio of cycloheximide-treated versus untreated cells. Cases homozygous
for c.1295C>G (n ¼ 2) showed an 8-fold increase, which was signiﬁcantly greater than the 2-fold differential increase observed in
controls (n ¼ 3, p < 0.001, Student’s t test). Data represent the mean differential expression 5 standard error of, respectively, three
control samples and two case samples.heterozygote state for a premature termination (c.191
dupA) and missense (c.692G>T, G231V) mutations. These
results strongly suggest that the two variants c.1295C>G
and c.191 dupA are associated with a loss of ANO5 func-
tion. Previously, dominant ANO5 mutations have been
reported in two families with gnathodiaphyseal dysplasia
(GDD [MIM 166260]), a rare skeletal syndrome character-
ized by bone fragility, cement-osseous lesions of the
maxilla and mandible, and diaphyseal sclerosis of tubular
bones.28 In these patients no other abnormalities in
nonskeletal tissues have been reported.28 The missense
mutations in GDD patients affect a conserved cysteine
located in an extracellular loop of ANO5, similar to the
R758C mutation found in MMD3 patients (Figure 2D).
However, because GDD is a dominant disease, it was
hypothesized that the mutations in these patients cause
a gain-of-function effect predominantly in skeletal
tissues.28 The only two available polyclonal antibodies
generated against N- and C-terminal epitopes of mouse
Ano529 failed to recognize the normal human protein on
western blots generated from transfected HeLa and Cos-1
cell lysates. By immunoﬂuorescence, nonspeciﬁc peri-
membranous and cytoplasmic staining was detected in
skeletal muscle (data not shown), thereby precluding the
testing of the impact of the mutations on the expression
and localization of ANO5 in patient muscle.
Table 1 summarizes the clinical ﬁndings for patients
carrying ANO5mutations that are also presented in greater
details in Table S1 available online. LGMD2L patients are
characterized by late-onset proximal scapular and pelvic
girdle muscle weakness (mean age 34.4, 20–55), accompa-
nied by asymmetrical atrophy of the quadriceps femoris
and biceps brachii.21 Though calf hypertrophy can be
observed at presentation, they may develop later in the
course asymmetrical mild calf atrophy usually not associ-
ated with weakness. No distal weakness in the upper limbs
was observed. None of the LGMD2L patients lost walking,
though the proximal weakness led to difﬁculties climbingThe Americastairs. The intrafamilial variability is striking with two
patients reporting no symptoms at ages 68 (IX-II-3) and
61 (XXXI-II-3), though mild iliopsoas weakness was docu-
mented on examination and the creatine kinases (CK)
levels were known to be elevated in the past years for
both cases (Table 1). The phenotype is quite different for
MMD3 patients. The Dutch patients (family IV) showed
early calf weakness, along with difﬁculties of walking on
tiptoes, without atrophy.23,24 In the Finnish patients
(family H), calf hypertrophy was seen in both cases during
the early stages of their disease, but case H-II-6 later devel-
oped asymmetric calf atrophy. Despite the hypertrophy,
calf weakness has always been an initial manifestation of
all MMD3 cases. Asymmetric involvement of the proximal
muscles of the lower and upper limb-girdles is a later mani-
festation with quadriceps atrophy being observed with
time in two out of ﬁve MMD3 patients (Table 1 and Table
S1). The FC case XXIX-II-1, which shares the exon 5 c.191
dupA mutation with the MMD3 Dutch Family IV, had a
somewhat overlapping LGMD2L and MMD3 phenotype.
At age 63, she had concomitant late-onset asymmetrical
proximal upper limb (deltoid, biceps, triceps) and ilopsoas
weakness and distal upper limb (wrist and ﬁnger extensors)
and tibialis anterior weakness, while having asymmetrical
normal strength gastrocnemius hypertrophy. CK were
elevated in all patients (1032-15860IU, mean 5514IU).
No cardiac abnormalities were detected on electrocardio-
myogram (ECG), Holter ECG, and echocardiography for
the FC and the Dutch patients. Electron microscopy per-
formed on muscle from the LGMD2L patient IX-II-921
and MMD3 patient H-II-6 (Figure 2C) both showed multi-
focal disruption of the sarcolemmal membrane but no sub-
sarcolemmal vesicle accumulation, as has been reported in
dysferlinopathies.30,31 Furthermore, in the MMD3 Family
H, membrane repair capability was found to be defective
in patient ﬁbroblasts by testing membrane resealing ability
via either multiphoton laser irradiation or glass-bead-
mediated wounding in the presence of ﬂuorescent dyes,n Journal of Human Genetics 86, 213–221, February 12, 2010 217
Table 1. Clinical Data of Patients Carrying ANO5 Mutations
Phenotype Fam-IDa
Ethnic
Bckg Sex
ANO5 Mutations
(gDNA)
Age
(2009)
Age of
Onset
Distal
Weakness Arm
Iliops.
MRC
Quad.
Atrophy
Quad.
MRC
Calf
Muscles
Distal
Weakness Leg
Loss of
Walking
Maximum
CK (IU)
LGMD2L IX-II-321 FC F c.1295C>Gb 68 AS none 4/5 þ 5/5 none none no 1,649
LGMD2L IX-II-421 FC M c.1295C>Gb 67 40 none 4/5 þ 4.5/5 mild atrophy none no 1,032
LGMD2L IX-II-521 FC M c.1295C>Gb 65 37 none 4/5 þ 4/5 mild atrophy none no 1,156
LGMD2L IX-II-921 FC M c.1295C>Gb 47 20 none 4/5 þ 5/5 mild atrophy none no 6,000
LGMD2L XXXI-II-11 FC M c.1295C>Gb 43 20 none 4/5 þ 5/5 atrophy calf muscles 4/5 no 8,081
LGMD2L XXXI-II-3 FC F c.1295C>Gb 61 AS none 4.5/5 - 5/5 hypertrophy none no 4,061
LGMD2L XXIX-II-1 FC F c.191 dupA/c.692G>T 64 55 none 3.5/5 þ 4.5/5 hypertrophy tibialis ant.4/5 no 1,339
MMD3 H-II-624 Fin M c.2272C>Tb 44 20 none Sin 4/5 þ 4/5/2/5 hypertrophy calf muscles 2/5 no 15,860
MMD3 H-II-424 Fin M c.2272C>Tb 50 25 none 5/5 - 5/5 hypertrophy calf muscles 4/5 no 12,290
MMD3 IV-II-123 Du M c.191 dupAb 72 51 none 4/5 - 4/5 none calf muscles 2/5 no 5,400
MMD3 IV-II-423 Du M c.191 dupAb 67 45 none 5/5 þ 5/5 none calf muscles 2/5 no 4,500
MMD3 IV-II-1223 Du M c.191 dupAb 53 39 none 5/5 - 5/5 none calf muscles 2/5 no 4,800
Means 37 5,514
Abbreviations: Ethnic bckg, ethnic background; FC, French Canadian; Fin, Finnish; Du, Dutch; AS, asymptomatic; Quad., quadriceps; Iliops., iliopsoas; MRC, Medical Research Council muscle strength scale; Tibialis ant.,
Tibialis anterior
a Families IX, H, and IV refer to original articles (see 21,23,24).
b Patients homozygous for the mutation.
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whereas lysosomal and enlargeosomal exocytosis was
shown to occur normally, indicating that the conventional
membrane repair pathways were not disrupted.24
Until recently the function of the Anoctamins was
unknown. The ten human ANO proteins share an eight
transmembrane domain structure, which led to their
earlier classiﬁcation as the TransMEMbrane Protein 16
(TMEM16) family, and a DUF590 domain of unknown
function.13,32 Three recent reports have demonstrated
that ANO1 corresponds to the elusive calcium-activated
chloride channel (CaCC).15–17 In one of these studies,
Schroeder et al. demonstrated that Ano1 coded for the
CaCC responsible for polyspermia blockade in Xenopus
oocytes.16 Since then several other independent studies
conﬁrmed that ANO1 and ANO2 function as CaCC in
mouse and in human.18–20,33,34 ANO6, ANO8, and ANO9
were also conﬁrmed to be chloride channels implicated
in the control of cellular volume.20 Because of the signiﬁ-
cant structural similarity between members of the Anocta-
min family, it is predicted that all these proteins, including
ANO5, are likely to function as CaCC. The physiological
roles attributed to CaCC, ranging from epithelial transport
of electrolytes, cell volume control, olfactory and photore-
ceptor transduction, and cardiac membrane excitability to
smooth muscle contraction, still remain unclear in many
tissues.35 Until now no CaCC conductance has been re-
ported in the plasma membrane of skeletal muscles, but
the high sarcolemmal chloride conductance owing to
the voltage-dependant chloride channel (CLCN1 [MIM
118425]) may have precluded the electrophysiological
observation of such activity.36 Calcium-activated chloride
channels have also been reported in sarcoplasmic retic-
ulum vesicles from rabbit skeletal muscles37 but appeared
to respond to much higher calcium concentrations than
the one observed for ANO1.17 A chloride current has
been observed after membrane wounding of sea urchin
embryos,38 which raises the possibility that ANO5 may
be responsible for a chloride current needed during
membrane repair in human muscle. Several additional
lines of evidence suggest that ANO5 may be important in
the development and maintenance of skeletal muscle:
ANO5 during embryogenesis is ﬁrst expressed in the
somites, particularly in the myotomal cells, and then in
the muscle progenitor cells;29 it is mostly expressed in skel-
etal muscle tissue in adult mice25 and in skeletal muscle
and cardiac tissues in human;28 its expression is increased
in dystrophin-deﬁcient mdx mice muscle;29 and lastly
ANO5 is upregulated during myogenic differentiation of
cultured cells (C2C12, Sol8, L6).29 The identiﬁcation of
recessive ANO5 mutations in patients with muscular
dystrophies associated with sarcolemmal membrane
lesions on electron microscopy and defective membrane
repair documented on one MMD3 family raise the possi-
bility that ANO5 may play an important role in the dysfer-
lin-dependent muscle membrane repair pathway. By
biochemical fractionation ANO5 has been shown to be
present at the membrane and in vesicles in L6 myotubesThe Americaand mouse skeletal muscle.29 Dysferlin shows a similar
distribution in C2C12 myotubes and muscle tissue.39,40
Dysferlin was identiﬁed as the ﬁrst protein component of
the sarcolemmal repair machinery and is predicted to func-
tion as a fusogen in the formation of the patch membrane
required for membrane resealing.8 Other proteins medi-
ating with dysferlin in muscle membrane repair have
been identiﬁed and include Tripartite motif-containing
72 (TRIM72),41 Annexins (MIM 151690, 151740),42,43
AHNAK (MIM 103390),44 and Caveolin-3.6,45 It could be
hypothesized that ANO5 present in vesicular membranes
may respond to the intracellular calcium inﬂux known to
occur with membrane damage46 by leading to a chloride
inﬂux in the vesicle that modiﬁes its conformation so
that it is recruited to the damage site.8 The observation
that ANO5 mutations, as in dysferlinopathy, can lead to
both a proximal and a distal muscular dystrophy further
suggests that anoctaminopathies may also cause skeletal
muscle demise through defective membrane repair.Supplemental Data
Supplemental Data include one table and can be found with this
article online at http://www.cell.com/AJHG.Acknowledgments
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